Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Firdapse is most often covered alongside Agamree, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6 in the same window.
Last mentioned: Feb 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Firdapse is most often covered alongside Agamree, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6 in the same window. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. We currently track 1 Healthcare story that mention Firdapse, all published on February 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Firdapse. Shared-story counts are live from our verified record — not editorial picks.
Root and Catalyst Pharmaceuticals are scheduled to release their quarterly financial results this Wednesday, providing critical data points for the insurtech and orphan drug sectors. Investors are looking for Root's progress toward profitability and Catalyst's continued dominance in the LEMS market.
Source: tickerreport.com · dailypolitical.com
Firdapse is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
